Based on systematic review evidence, the Task Force provided a recommendation against screening for prostate cancer using the PSA test for adults less than 55 years of age (strong recommendation; low-quality evidence), adults 55 to 69 years of age (weak recommendation; moderate quality evidence), and adults 70 years of age and older (strong recommendation; low-quality evidence). This evidence concerns the gene KLK3 and prostate cancer.